Why Is Omeros Stock Trading Lower Tuesday?
Omeros shares slide after mixed Q3 results—Yartemlea sales jump 26% sequentially, but revenue misses and EU setbacks weigh.
Last updated: 2026-11-19 07:29:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Omeros Corporation (OMER) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14.52, with a market capitalization of $1.04B and a P/E ratio of 10.54. Over the past 52 weeks, its price has ranged from $6.70 to $21.24. This page covers its latest market performance, valuation, price trends and company information.
$1.04B | |
$14.14 | |
$14.75 | |
$13.85 | |
$13.92 | |
2.20M | |
1.37M | |
10.54 | |
$21.24 | |
$6.70 | |
-- | |
2026-06-30 |
Omeros Corporation (OMER) last closed at $14.52 as of 2026-11-19 00:48:00, up 4.42% ($0.62) from the previous close of $13.92.
During the latest regular trading session, OMER traded between $13.85 and $14.75, with a volume of 2.20M shares. The closing price was near the upper end and near the middle of its 52-week range.
OMER is up 4.42% as of the last close.
Over the past seven days, Omeros Corporation (OMER) moved from $17.30 to $14.52, representing a decline of 16.05% ($2.78).
The stock traded between $12.70 and $18.18 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 1.77 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 53.8%
OMER is currently trading at $14.52, placing it 53.8% of the way from its 52-week low of $6.70 to its 52-week high of $21.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 175 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Omeros Corporation and OMER stock.
Omeros shares slide after mixed Q3 results—Yartemlea sales jump 26% sequentially, but revenue misses and EU setbacks weigh.
HC Wainwright & Co. analyst Brandon Folkes reiterates Omeros (NASDAQ:OMER) with a Buy and maintains $33 price target.
U.S. stock futures fell as Red Cat plunged 25.8% after weak Q3 results and withdrawing FY26 guidance; several stocks also declined premarket.
Gainers Dare Bioscience (NASDAQ:DARE) shares rose 9.5% to $0.64 during Monday's after-market session. The company's market cap stands at $12.9 million. As per the press release, Q3 earnings came out today.
Omeros (NASDAQ:OMER) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 117.65 percent increase over losses of $(0.34) per share from the same
Eligible investors can buy real shares of Omeros Corporation (OMER) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to OMER, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between OMER shares and USD.
OMER Shares to USD
1.00 OMER shares = 14.523 USD
Calculations are estimates based on the latest available price and are for reference only.